Hypha Labs, Inc.
Hypha Labs, Inc.
Your view on FUNI
Overview
What the company does, where it operates, and who runs it.
About Hypha Labs, Inc.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- A. Stone Douglass
- Headquarters
- 5940 S. Rainbow Boulevard, Las Vegas, NV, US
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- A. Stone Douglass
- Headquarters
- 5940 S. Rainbow Boulevard, Las Vegas, NV, US
Hypha Labs, Inc., engages in the research, development, and commercialization of a bioreactor in the United States. It offers Hypha Micropearl bioreactor, a home appliance designed to accelerate the production of beneficial mushrooms for human consumption. Hypha Labs, Inc. was incorporated in 2010 and is headquartered in Las Vegas, Nevada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Hypha Labs, Inc., and the rating behind it. FUNI last traded at $0.03; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Hypha Labs, Inc.. Starting points for Hypha Labs, Inc.: EPS -$0.01, beta 1.21 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Hypha Labs, Inc.. Hypha Labs, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Hypha Labs, Inc.. Trailing twelve-month EPS for Hypha Labs, Inc. stands at -$0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Hypha Labs, Inc.. Hypha Labs, Inc. has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Hypha Labs, Inc. valued side by side against its closest peers. Hypha Labs, Inc. is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Hypha Labs, Inc., and how their positions are changing. At a $4.0M market value, institutional positions materially move Hypha Labs, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Hypha Labs, Inc. executives and directors. Shares of Hypha Labs, Inc. have traded between $0.0053 and $0.04 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Hypha Labs, Inc.. Hypha Labs, Inc. is a $4.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Hypha Labs, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Hypha Labs, Inc.. Coverage tracks Hypha Labs, Inc. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.